Big Pharma Split Corp Class A (PRM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Big Pharma Split Corp Class A (PRM) has a cash flow conversion efficiency ratio of -0.011x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-144.04K ≈ $-104.19K USD) by net assets (CA$13.14 Million ≈ $9.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PRM defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Big Pharma Split Corp Class A - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Big Pharma Split Corp Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Big Pharma Split Corp Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Big Pharma Split Corp Class A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ostasiatiske Kompagni A/S
CO:OKEAC
|
0.526x |
|
Aterian Inc
NASDAQ:ATER
|
-0.069x |
|
Infrared Cameras Holdings Inc
NASDAQ:MSAI
|
-0.070x |
|
Jianzhi Education Technology Group Company Limited American Depositary Shares
NASDAQ:JZ
|
0.736x |
|
Wise Group AB
ST:WISE
|
0.075x |
|
New Era Helium Inc Common Stock
NASDAQ:NEHC
|
0.362x |
|
Armlogi Holding Corp. Common Stock
NASDAQ:BTOC
|
-0.157x |
|
TS Corp Preference Shares
KO:001795
|
0.047x |
Annual Cash Flow Conversion Efficiency for Big Pharma Split Corp Class A (2017–2024)
The table below shows the annual cash flow conversion efficiency of Big Pharma Split Corp Class A from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Big Pharma Split Corp Class A stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$13.68 Million ≈ $9.90 Million |
CA$-1.30 Million ≈ $-937.16K |
-0.095x | -112.66% |
| 2023-12-31 | CA$15.85 Million ≈ $11.47 Million |
CA$11.86 Million ≈ $8.58 Million |
0.748x | +1208.10% |
| 2022-12-31 | CA$19.73 Million ≈ $14.27 Million |
CA$1.13 Million ≈ $816.29K |
0.057x | +114.24% |
| 2021-12-31 | CA$22.40 Million ≈ $16.21 Million |
CA$-9.00 Million ≈ $-6.51 Million |
-0.402x | -221.81% |
| 2020-12-31 | CA$13.19 Million ≈ $9.54 Million |
CA$4.35 Million ≈ $3.15 Million |
0.330x | -38.03% |
| 2019-12-31 | CA$16.31 Million ≈ $11.80 Million |
CA$8.68 Million ≈ $6.28 Million |
0.532x | +689.14% |
| 2018-12-31 | CA$18.84 Million ≈ $13.63 Million |
CA$1.27 Million ≈ $919.19K |
0.067x | +104.07% |
| 2017-12-31 | CA$18.68 Million ≈ $13.51 Million |
CA$-30.95 Million ≈ $-22.39 Million |
-1.657x | -- |
About Big Pharma Split Corp Class A
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.